Novel Agents Now Prevalent Method of Care for Multiple Myeloma

A majority of patients with multiple myeloma are being treated with novel agents such as thalidomide, bortezomib, and lenalidomide within a year of diagnosis instead of the chemotherapeutic regimens that were more prevalent a decade ago, according to a new study.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news